Monotherapy for estrogen receptor +ve, locally advanced or metastatic breast cancer in postmenopausal women who are human epidermal growth factor receptor 2 (HER2) -ve & not previously treated w/ endocrine therapy, or -w/ disease relapse on or after adjuvant endocrine therapy, or disease progression on endocrine therapy. In combination w/ ribociclib for hormone receptor (HR) +ve, HER2 -ve advanced or metastatic breast cancer in postmenopausal women as initial therapy or following disease progression on endocrine therapy. In combination w/ abemaciclib for women w/ HR +ve, HER2 -ve advanced or metastatic breast cancer w/ disease progression following endocrine therapy. In combination w/ palbociclib for HR +ve, HER2 -ve locally advanced or metastatic breast cancer in women who have received prior endocrine therapy.
Sign Out
 250 mg_5 mLd2791556-3e02-4b42-b91b-9faa000a41fc.GIF)
